Related Experiment Videos

High dose chemotherapy for breast cancer: taking stock

J O'Shaughnessy¹

¹Chemoprevention Research, US Oncology, Inc., Dallas, Texas 75246, USA. Joyce.O'Shaughnessy@usoncology.com

|March 8, 2000

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.

ESMO open·2026

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials.

ESMO open·2026

Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer.

ESMO open·2026

Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.

ESMO open·2026

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

See all related articles